Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 36.43 | 03:09:34 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 36.43 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 22.11 - 53.18 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 36.43 | USD |
Celldex Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.04B | 55.90M | - | 6.88M | -141.43M | -2.53 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Celldex Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 34.70 | 37.37 | 34.01 | 35.50 | 625,660 | 1.73 | 4.99% |
| 1 Month | 40.10 | 40.22 | 32.25 | 35.30 | 630,796 | -3.67 | -9.15% |
| 3 Months | 41.63 | 43.35 | 32.25 | 38.37 | 619,448 | -5.20 | -12.49% |
| 6 Months | 35.86 | 53.18 | 32.25 | 41.08 | 787,619 | 0.57 | 1.59% |
| 1 Year | 38.25 | 53.18 | 22.11 | 36.07 | 693,579 | -1.82 | -4.76% |
| 3 Years | 31.04 | 57.20 | 19.85 | 35.99 | 636,537 | 5.39 | 17.36% |
| 5 Years | 2.51 | 57.20 | 1.50 | 25.59 | 668,924 | 33.92 | 1,351.39% |
Celldex Therapeutics Description
| Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
